drugset / Trial / NCT03293784
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1b, open-label study of immune checkpoints inhibitors Nivolumab+Ipilimumab administered in combination with the anti-TNF-α either Infliximab or Certolizumab, in patients with advanced melanoma.
Timeline
- Start
- 2017-10-16
- Primary completion
- 2019-12-06
- Completion
- 2023-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab | Protein / enzyme biologic | 200 mg | Other |
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | Other |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Other |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Other |